Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gynecologic 5

Conditions

Ovarian Neoplasms 11Prostatic Neoplasms 7Fallopian Tube Neoplasms 5Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Prostate Adenocarcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioma 1Endometrial Neoplasms 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Paclitaxel 24Bevacizumab 21Carboplatin 20liposomal doxorubicin 15Specimen Handling 14Magnetic Resonance Spectroscopy 13olaparib 12Gemcitabine 10Topotecan 9pembrolizumab 8Biopsy 8Taxes 7Immunoglobulin G 6Disulfides 6niraparib 5Doxorubicin 5mirvetuximab soravtansine 4cediranib 4oregovomab 3Nivolumab 3Drug Therapy 3Docetaxel 3Cisplatin 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Saline Solution 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × niraparib × 90 days × Clear all
NCT04295577 2026-05-13

MONITOR-UK

Royal Marsden NHS Foundation Trust

Completed
388 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-05-04

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

CanariaBio Inc.

Phase 2 Active not recruiting
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05198804 2026-03-18

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 1/2 Completed
117 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡